Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Mereo BioPharma Group plcNASDAQ: MREO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $304.49K rose 12.8% year over year, behind the +15.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 48.6% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.

Context

  • Depreciation & amortization amounted to 229.8% of revenue in FY2025.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +12.8% toward the trailing-twelve-month pace of +15.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$304.49K-48.6% QoQ
Last fiscal yearDec 2025
$1.15M+5.6% YoY
LTMMar 2026
$1.25M+15.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.8%——
1 year+5.6%——
3-year CAGR+8.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.15M USD
Year-over-year change
+5.6%
4-year CAGR
+7.3%

Depreciation & Amortization vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.6% is the 3rd highest of 10, against a peer median of +3.1%.
  • Depreciation & amortization amounts to 249.7% of revenue for MREO, versus a peer median of 42.9%.
MREO Competitors
Depreciation & Amortization for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1B USD+66925.2%+52.5%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
IMMPImmutep LimitedFY2025A$2.13M AUD+6.0%+5.1%42.3%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$2.12M USD+4.8%+22.0%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$1.65M USD-13.9%+19.6%—
ACIUAC Immune S.A.LTM Mar 2026CHF 1.61M CHF-27.3%+2.0%43.6%
MREOMereo BioPharma Group plcLTM Mar 2026$1.25M USD+15.6%+8.7%249.7%
CADLCandel Therapeutics, Inc.LTM Mar 2026$749K USD-23.9%+2.8%—
SLNSilence Therapeutics plcLTM Mar 2026$577.79K USD—+4.5%62.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
Peer median (excluding MREO) —+3.1%+3.7%42.9%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.